Avram Hershko

Avram Hershko
Amos Ben Gershom · CC BY-SA 3.0 · source
Name	Avram Hershko
Birth date	1937-12-31
Birth place	Karviná, Czechoslovakia
Nationality	Israeli
Fields	Biochemistry, Cell biology, Molecular biology
Alma mater	Technion – Israel Institute of Technology
Known for	Discovery of the ubiquitin–proteasome system
Awards	Nobel Prize in Chemistry, Wolf Prize in Medicine, Lasker Award

Avram Hershko is an Israeli biochemist noted for elucidating the biochemical pathway that targets proteins for regulated degradation in cells, a discovery central to modern cell biology and molecular biology. His work, conducted with colleagues at research institutions in Israel and collaborations with laboratories worldwide, transformed understanding of protein turnover, intracellular signaling, and disease mechanisms such as cancer, neurodegenerative disease, and infectious disease. Hershko shared recognition for this breakthrough with fellow researchers whose combined findings established the ubiquitin–proteasome system as a fundamental cellular apparatus.

Early life and education

Hershko was born in Karviná, then part of Czechoslovakia, and after surviving the upheavals of World War II he and his family emigrated to Israel. He studied at the Technion – Israel Institute of Technology, where he received degrees in chemistry and completed doctoral work in biochemical studies under mentors connected to research networks that included laboratories influenced by figures such as Aaron Ciechanover and others in the Israeli biochemical community. During his formative years he trained in experimental techniques developed in laboratories linked to the broader European and North American traditions exemplified by institutions like the Weizmann Institute of Science and universities such as Hebrew University of Jerusalem.

Scientific career

Hershko built a research program at the Technion – Israel Institute of Technology and later held positions that fostered collaboration with researchers at institutions including the University of California, San Francisco, the Max Planck Society, and the National Institutes of Health. His laboratory combined biochemical fractionation, enzymology, and emerging molecular approaches, drawing on conceptual frameworks advanced by investigators at the Massachusetts Institute of Technology, Rockefeller University, and the European Molecular Biology Laboratory. He collaborated with contemporaries who were instrumental in characterizing enzymatic cascades and protein modifications, groups connected to Nobel-recognized work at organizations like Harvard University and Columbia University.

Discovery of the ubiquitin–proteasome system

Hershko, together with colleagues, identified the pathway whereby proteins are marked by the small protein ubiquitin for selective degradation by the proteasome, integrating biochemical findings with genetic and cell biological evidence from groups such as those at Stanford University and Yale University. The discovery built on enzymatic paradigms like E1, E2, and E3 activities characterized by teams linked to the University of Cambridge and the Cold Spring Harbor Laboratory, and it clarified mechanisms relevant to regulatory systems exemplified by signaling pathways studied at Salk Institute for Biological Studies and Johns Hopkins University. Their work established how post-translational modification by ubiquitin interfaces with pathways implicated in oncology research at institutions like Memorial Sloan Kettering Cancer Center and neurobiology programs at the University of California, San Diego.

The elucidation of the ubiquitin–proteasome system catalyzed translational advances, informing drug development efforts at pharmaceutical centers such as Pfizer and biotech companies originating from campuses like MIT and Stanford University. Clinical applications targeted proteasome function to treat malignancies exemplified by collaborative trials involving hospitals such as Mayo Clinic and Dana–Farber Cancer Institute.

Awards and honors

Hershko's contributions were recognized by major scientific prizes including the Nobel Prize in Chemistry (shared), the Wolf Prize in Medicine, and the Albert Lasker Basic Medical Research Award, aligning him with laureates from institutions like Karolinska Institute and the Royal Society. He received honorary degrees and memberships in academies such as the National Academy of Sciences, the Israel Academy of Sciences and Humanities, and international societies tied to organizations like the American Association for the Advancement of Science and the European Molecular Biology Organization. His awards acknowledged impacts echoed by prizewinners from centers such as ETH Zurich and the University of Tokyo.

Personal life and legacy

Hershko's legacy is reflected in ongoing research at centers like the Weizmann Institute of Science, the Broad Institute, and university laboratories in Europe and North America that continue to explore ubiquitin-mediated regulation in contexts ranging from immunology at National Jewish Health to developmental biology at Princeton University. His mentorship influenced scholars who established laboratories at institutions such as the University of Pennsylvania and Tel Aviv University, contributing to a global network of investigators in biotechnology and pharmacology. Outside the laboratory, he has been associated with academic leadership roles typical of senior scientists affiliated with universities including the Technion – Israel Institute of Technology and advisory positions to research foundations and biomedical companies.

Category:Israeli biochemists Category:Nobel laureates in Chemistry Category:Technion – Israel Institute of Technology faculty